AMEX: SYN | Healthcare / Biotechnology / USA |
0.6500 | +0.0100 | +1.56%![]() | Vol 101 018 | 1Y Perf -95.81% |
Feb 21st, 2019 16:00 |
BID | 0.0000 | ASK | 0.0000 | ||
Open | 0.6500 | Previous Close | 0.6400 | ||
Pre-Market | - | After-Trading | - | ||
- -% | - -% |
Target Price | 6.00 | Analyst Rating | Strong Buy 1.00 | |
Potencial % | 823.08 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12M | -/-/- | Value Ranking | — - | |
Insiders Value % 3/6/12M | -/-/- | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12M | -/-/- | Income Ranking | — - | |
Market Cap (mil) | 9 | Earnings Rating | Strong Buy | |
Price Range Ratio 52wk % | 0.96 | Earnings Date | 28th Feb 2019 |
Today's Price Range 0.62000.6500 | 52wk Range 0.510015.05 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Month | 0.00% | ||
3 Months | -19.75% | ||
6 Months | -77.97% | ||
1 Year | -95.81% | ||
3 Years | -98.58% | ||
5 Years | -99.30% |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Quick Ratio | 2.50 | |||
Current Ratio | 2.60 | |||
Long Term Debt to Total Capital | - | |||
Total Debt to Equity | - | |||
Interest Coverage | - | |||
Leverage Ratio | -2.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Gross Margin | - | |||
EBIT Margin | - | |||
EBITDA Margin | - | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 21.96 | |||
PS Ratios | - | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -0.60 | |||
Cash Flow Per Share | -3.35 | |||
Price to Tangible Book | -2.26 | |||
Book Value per Share | -0.28 | |||
Enterprise Value (in ths.) | -1 120 |
Management Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Return on Equity (5Y Avg) | -263.46 | |||
ROE last 12 Months | 74.59 | |||
Return on Assets (5Y Avg) | -151.04 | |||
ROA last 12 Months | -44.84 | |||
Return on Capital (5Y Avg) | -909.73 | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -1 886.50 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Revenue LTM (in ths.) | 0 | |||
Revenue per Share | 0.00 | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2018 | -1.32 | -0.93 | 29.55 |
Q02 2018 | -1.40 | -1.05 | 25.00 |
Q01 2018 | -1.75 | -0.70 | 60.00 |
Q04 2017 | -1.75 | 0.70 | 140.00 |
Q03 2017 | -1.75 | -4.90 | -180.00 |
Q02 2017 | -2.45 | -1.05 | 57.14 |
Q01 2017 | -0.07 | -0.02 | 71.43 |
Q04 2016 | -0.09 | -0.02 | 77.78 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2018 QR | -0.17 | 74.24 | Positive |
12/2018 FY | -2.36 | 48.25 | Positive |
3/2019 QR | -0.16 | 0.00 | - |
12/2019 FY | -0.67 | 84.20 | Positive |
Next Report Date | 28th Feb 2019 |
Estimated EPS Next Report | -0.17 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 101 018 |
Shares Outstanding (in ths.) | 13 483 |
Trades Count | 147 |
Dollar Volume | 61 441 |
Avg. Volume | 198 245 |
Avg. Weekly Volume | 90 858 |
Avg. Monthly Volume | 146 380 |
Avg. Quarterly Volume | 218 105 |
Week | Month | Three Months | Six Months |
---|---|---|---|
Bearish Bullish 50%50% | Bearish Bullish 68%32% | Bearish Bullish 35%65% | Bearish Bullish 63%37% |
There are no comments yet.
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |